Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
C Hirsch, YS Park, V Piechotta, KL Chai… - Cochrane Database …, 2022 - cochranelibrary.com
Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as potential prophylaxis to …
from the B cells of an infected host. They are being investigated as potential prophylaxis to …
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID …
BACKGROUND Bebtelovimab is a potent, fully human IgG1 monoclonal antibody (mAb)
targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known …
targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known …
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …
antibody regimens for COVID-19. Methods This systematic review and random-effects …
The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination
RJ Benschop, JL Tuttle, L Zhang… - Science Translational …, 2022 - science.org
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout
progresses, the availability and demand for monoclonal antibodies for the prevention and …
progresses, the availability and demand for monoclonal antibodies for the prevention and …
Rapid isolation of anti-idiotype aptamers for quantification of human monoclonal antibodies against SARS-CoV-2 spike protein
Therapeutic antibodies that block viral entry have already proven to be important, first line
drugs for treatments of viral infections. In the case of SARS-CoV-2, combinations of multiple …
drugs for treatments of viral infections. In the case of SARS-CoV-2, combinations of multiple …
A quantitative modeling and simulation framework to support candidate and dose selection of anti‐SARS‐CoV‐2 monoclonal antibodies to advance bamlanivimab …
E Chigutsa, E Jordie, M Riggs, A Nirula… - Clinical …, 2022 - Wiley Online Library
Neutralizing monoclonal antibodies (mAb), novel therapeutics for the treatment of
coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome …
coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome …
Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual
Prolonged infections in immunocompromised individuals may be a source for novel Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, particularly when both …
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, particularly when both …
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
SY Yu, M Choi, C Cheong, S Ryoo, K Huh… - Journal of Microbiology …, 2023 - Elsevier
This study evaluated the efficacy and safety of neutralizing monoclonal antibodies (mAbs)
with usual care in patients with coronavirus disease 2019 (COVID-19). Randomized …
with usual care in patients with coronavirus disease 2019 (COVID-19). Randomized …